THTX vs. URGN, ARVN, TSHA, CGEM, ETON, ALT, SANA, MGTX, MAZE, and SIGA
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include UroGen Pharma (URGN), Arvinas (ARVN), Taysha Gene Therapies (TSHA), Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs.
UroGen Pharma (NASDAQ:URGN) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
UroGen Pharma received 348 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 74.17% of users gave UroGen Pharma an outperform vote while only 54.39% of users gave Theratechnologies an outperform vote.
UroGen Pharma presently has a consensus target price of $31.00, indicating a potential upside of 659.80%. Given UroGen Pharma's higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Theratechnologies.
Theratechnologies has a net margin of -3.75% compared to UroGen Pharma's net margin of -129.11%.
91.3% of UroGen Pharma shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, UroGen Pharma had 26 more articles in the media than Theratechnologies. MarketBeat recorded 26 mentions for UroGen Pharma and 0 mentions for Theratechnologies. UroGen Pharma's average media sentiment score of 0.20 beat Theratechnologies' score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the media.
Theratechnologies has lower revenue, but higher earnings than UroGen Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Summary
UroGen Pharma beats Theratechnologies on 12 of the 18 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy THTX Stock Free THTX Stock Alerts